Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Harnessing preclinical mouse models to inform human clinical cancer trials
David H. Gutmann, … , Kim Hunter-Schaedle, Kevin M. Shannon
David H. Gutmann, … , Kim Hunter-Schaedle, Kevin M. Shannon
Published April 3, 2006
Citation Information: J Clin Invest. 2006;116(4):847-852. https://doi.org/10.1172/JCI28271.
View: Text | PDF
Review

Harnessing preclinical mouse models to inform human clinical cancer trials

  • Text
  • PDF
Abstract

The urgent need for better cancer treatments has stimulated interest in employing small-animal models to evaluate potential drug therapies. Robust mouse models of many human cancers have been generated using sophisticated technologies for engineering germ-line mutations. As we enter into an age of targeted therapeutics, these strains provide novel platforms for validating new anticancer drugs, assessing therapeutic index, identifying surrogate markers of tumor progression, and defining epigenetic and environmental influences on tumorigenesis.

Authors

David H. Gutmann, Kim Hunter-Schaedle, Kevin M. Shannon

×

Figure 1

Use of GEM tumor models as “filters” to select agents for human clinical trials.

Options: View larger image (or click on image) Download as PowerPoint
Use of GEM tumor models as “filters” to select agents for human clinical...
One strategy has been proposed for use in the Nf1 GEM models community, which involves the evaluation of new therapies in multiple mouse strains. New drugs would be rapidly screened using MPNST and leukemia GEM models for efficacy (therapeutic index), target validation, and potential “off-target” effects. These GEM models would be utilized for initial evaluation, based on the rapid growth of the tumors and the relative ease of measuring tumor growth. Drugs that exhibit activity in these models would be further analyzed in detailed PK/PD studies in other tumor models, such as orthotopic tumor explant models and transgenic mice harboring specific deregulated cancer-associated molecules or pathways. Optic glioma and neurofibroma (plexiform neurofibroma) GEM models may be better suited for chemoprevention studies as well as investigations of drugs that target specific cells in the tumor microenvironment (e.g., microglia and mast cells). Collectively, the combined use of each of the available robust preclinical GEM models would afford researchers the opportunity to comprehensively evaluate drugs prior to considering human clinical trials. Adapted with permission from a summary presentation by Susan Blaney, Cold Spring Harbor Laboratories, Banbury Center conference on “Barriers and Solutions in the Use of Mouse Models to Develop Therapeutic Strategies for Neurofibromatosis-Associated Tumors,” November 3–5, 2005.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts